While the global trend is towards a “more hostile IP environment” for pharmaceutical companies, Danish healthcare giant Novo Nordisk A/S continues to perform. LSIPR talks to Lars Kellberg, corporate vice president, about how it meets the challenges.
There are important differences between the Russian and Eurasian procedures in obtaining a patent, especially for inventions in the field of life sciences, as Maria Nilova and Elena Tsvetkova explain.
The sweeping reform brought about by the AIA includes the FITF patent system, which places a premium on maintaining confidentiality, and speed and efficiency in filing patent applications while juggling the uncertainties and nuances of this new system.
In its effort to tackle the threat of ‘evergreening’, the CJEU has caused some uncertainty about supplementary protection certificates, as Jaap Mannaerts explains.
Challenging the validity of a patent through the court systems of Europe and the US can be a time-consuming and expensive process. Jane Wainwright and Daniel Young look at the alternatives.
On March 16, 2013, the ‘first inventor to file’ provisions of the AIA came into effect. MaryAnne Armstrong looks at the implications.
The recent agreement on a Unified Patent Court in Europe raises questions for patent holders in all industries. Trevor Cook looks at the potential impact on pharmaceutical patent litigation.
For a young innovation company, IP protection is all about ensuring comprehensive coverage. LSIPR spoke to David Diamond of MannKind Corporation about its threats and opportunities.
It seems an unlikely place for innovation, but Lille and its surroundings play host to a burgeoning life sciences industry. LSIPR visited to find out more.
For the Biotechnology Industry Organization, key developing markets pose particular challenges in terms of IP and also in a wider context. LSIPR spoke to Joe Damond and Lila Feisee about international affairs.